DxTerity Diagnostics and City of Hope Announce Therapeutics Collaboration
Complete the form below to unlock access to ALL audio articles.
DxTerity Diagnostics and City of Hope will collaborate on the development of therapeutic applications for DxTerity’s proprietary NEAT™ technology.
NEAT™ is a versatile genomics testing platform that enables gene-controlled ligation (joining) of oligonucleotide probes inside of cells (in-situ). This specific technique will be used to develop in-situ assembled antisense therapeutics. Unlike traditional therapeutics that work by binding to proteins, antisense therapeutics work at the genomic level to prevent the production of the unwanted protein by blocking the translation of mRNA.
The DxTerity approach differs from normal antisense therapeutics because the initial materials are designed to be inactive requiring in-situ activation that is dependant on the expression of the target gene. If successful, the resulting new class of molecules could display exquisite specificity with reduced side effects.
“Our goal is to utilize the unique properties available with the NEAT™ technology to overcome some of the current limitations associated with antisense therapeutics,” said Arthur. D. Riggs, Ph.D., Chair, Department of Diabetes & Metabolic Diseases Research and Emeritus Director, Beckman Research Institute of the City of Hope.
According to Dr. Bob Terbrueggen, President and founder of DxTerity Diagnostics, “DxTerity is excited to be collaborating with City of Hope, whose recognized experience and expertise in developing drugs should accelerate the progress of this new class of antisense therapeutics. Our hope is that their well-developed model systems and scientific expertise will enable the rapid identification and evaluation of new drug candidates.”
Terms of the agreement have not been disclosed.
